Two funny ladies, Jane Fonda and Lily Tomlin, went on a TV show with Stephen Colbert. They talked about using a plant called peyote that can make you see things when you take it. Jane said she would help Stephen try it if he wanted to, but he should not trust Lily's friend who knows about special plants because she is a different kind of funny lady. The story also talks about growing mushrooms at home and how some people like them for fun or health reasons. Read from source...

- The title is misleading and clickbaity, as it does not accurately reflect the content of the article. The main topic is not about "You Need A Little Peyote", but rather a conversation between Jane Fonda, Lily Tomlin, and Stephen Colbert on a late-night talk show.
- The article contains irrelevant information, such as mentioning Benzinga's research services and how to grow mushrooms at home, which have nothing to do with the interview or the topic of peyote use. This could be seen as an attempt to drive traffic or revenue from external sources, rather than focusing on the main story.
- The article lacks objectivity and critical analysis of the participants' views and opinions on peyote use. It simply reports what they said without providing any context, background, or evaluation of their statements. For example, it does not explain why Fonda and Tomlin are interested in peyote or shamanism, how they practice it, what effects it has on them, etc.
- The article uses informal language, slang, and jokes, which may appeal to a casual audience, but also undermine the credibility and professionalism of the journalism. For example, phrases like "she usually does", "that she's a bit more advanced in than Fonda", "jokingly gesturing not to trust Tomlin's shamanism", etc., are unnecessary and detract from the quality of the article.
- The article ends with an unrelated promotion for Benzinga Cannabis Conferences, which has nothing to do with peyote or the interview. This could be seen as a blatant advertisement, rather than a helpful resource for the readers.

Given that this is a humorous article about Jane Fonda, Lily Tomlin, and Stephen Colbert discussing peyote, there are no direct or clear investment implications from the content of the article. However, one could argue that the mention of peyote usage might be indicative of the growing interest and acceptance of psychedelics and alternative medicine in mainstream culture, which could potentially benefit companies involved in the production, research, or distribution of such substances. Additionally, the mention of mushroom cultivation could also be seen as a sign of increasing demand for mushrooms, either for recreational or medicinal purposes, which might benefit companies involved in that sector.

Based on these possible interpretations, some potential investment recommendations are:

- Compass Pathways (CMPS): A clinical-stage biopharmaceutical company specializing in the development of psilocybin-based therapies for various mental health disorders. Psilocybin is a psychedelic compound found in some species of mushrooms, including those containing peyote. Compass Pathways has recently gone public through a reverse merger with a SPAC and has received breakthrough therapy designation from the FDA for its lead product, which is currently undergoing phase 3 trials. The company has also partnered with various academic institutions and research centers to further investigate the safety and efficacy of psilocybin-based treatments. Compass Pathways could potentially benefit from the growing awareness and acceptance of psychedelics as a means for mental health treatment, as well as the increasing legalization and decriminalization of such substances in various jurisdictions around the world.

- Mydecine Innovations Group (MYCO): A biotechnology company focused on the development and commercialization of adaptive pathways to treat complex brain disorders. Mydecine has a diverse pipeline of products and therapies based on different psychedelic compounds, such as psilocybin, DMT, MDMA, LSD, and ketamine. The company also operates an online platform that connects patients with mental health professionals who can prescribe or recommend psychedelic-assisted therapies. Mydecine has recently gone public through a merger with Acer Therapeutics, which was previously involved in the development of a rare disease drug for children. Mydecine could potentially benefit from the growing interest and acceptance of psychedelics as a means for mental health treatment, as well as the increasing legalization and decriminalization of such substances in various jurisdictions around the world.

- Revive Therapeutics (RVVTF): A biotechnology company focused on the development of